Evidence map›Paper›PMID 34779658›Full record

Trial reportCirculation2022

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.

Javed Butler, Gerasimos Filippatos, Tariq Jamal Siddiqi, Martina Brueckmann, Michael Böhm, Vijay K Chopra, João Pedro Ferreira, James L Januzzi, Sanjay Kaul, Ileana L Piña and 10 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03057951. Cited by 96 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 5 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03057951 phase3completed

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Ran2017Enrolled5,988Registered outcomes10Posted comparisons10ConditionsHeart FailureArmsempagliflozin, Placebo
Open the trial in the graph
NCT04592445 narecruitingnot on this map

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study

TypeinterventionalSponsorAxon Therapies, Inc.Ran2020 to 2029Enrolled150ConditionsHeart Failure With Preserved Ejection Fraction (HFpEFArmsGreater Splanchnic Nerve Ablation, Sham Control
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 5 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Assessment of Exercise Intolerance and Evaluation for HFpEF: A Literature Review of Pathophysiology, Diagnosis, and Management.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  16. Article
  17. Review
  18. Review
  19. Improving the Analysis of KCCQ Endpoints in Heart Failure Clinical Trials.Therapeutic innovation & regulatory science · 2026
    Article
  20. Review

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 18 institutions in 13 countries.

Javed ButlerDepartment of Medicine, University of Mississippi School of Medicine, Jackson (J.B., T.J.S.).ORCID 0000-0001-7683-4720
Gerasimos FilippatosNational and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).ORCID 0000-0002-5640-0332
Tariq Jamal SiddiqiDepartment of Medicine, University of Mississippi School of Medicine, Jackson (J.B., T.J.S.).
Martina BrueckmannBoehringer Ingelheim International GmbH, Ingelheim, Germany (M. Brueckmann).ORCID 0000-0003-1215-0746
Michael BöhmKlinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany (M. Böhm).ORCID 0000-0002-2976-2514
Vijay K ChopraMax Superspeciality Hospital, Saket, New Delhi, India (V.K.C.).ORCID 0000-0001-9512-1718
João Pedro FerreiraUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., F.Z.).ORCID 0000-0002-2304-6138
James L JanuzziMassachusetts General Hospital and Baim Institute for Clinical Research, Boston (J.L.J.).ORCID 0000-0002-8338-1798
Sanjay KaulCedars-Sinai Medical Center, Los Angeles, CA (S.K.).ORCID 0000-0001-9640-4146
Ileana L PiñaCentral Michigan University, Mount Pleasant (I.L.P.).ORCID 0000-0002-4986-7129
Piotr PonikowskiWroclaw Medical University, Poland (P.P.).ORCID 0000-0002-3391-7064
Sanjiv J ShahNorthwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.).ORCID 0000-0002-5655-8201
Michele SenniCardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy (M.S.).
Ola VedinBoehringer Ingelheim AB, Stockholm, Sweden (O.V.).
Subodh VermaDivision of Cardiac Surgery, St. Michael's Hospital, University of Toronto, ON, Canada (S.V.).ORCID 0000-0002-4018-8533
Barbara PeilBoehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany (B.P.).
Stuart J PocockDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, United Kingdom (S.J.P.).
Faiez ZannadUniversité de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., F.Z.).ORCID 0000-0001-7456-1570
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).ORCID 0000-0003-1828-2387
Stefan D AnkerDepartment of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, Germany (S.D.A.).ORCID 0000-0002-0805-8683
Inserm · FRUniversity of Mississippi · USBaim Institute for Clinical Research · USBaylor University Medical Center · USBerlin-Brandenburger Centrum für Regenerative Therapien · DEBoehringer Ingelheim (Germany) · DEBoehringer Ingelheim (Sweden) · SECedars-Sinai Medical Center · USCentral Michigan University · USMax Super Speciality Hospital · INNational and Kapodistrian University of Athens · GRNorthwestern University · USOspedale Papa Giovanni XXIII · ITSt. Michael's Hospital · CATechnische Hochschule Mannheim · DEUniversitätsklinikum des Saarlandes · DEUniversity of London · GBWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with heart failure with preserved ejection fraction have significant impairment in health-related quality of life. In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), we evaluated the efficacy of empagliflozin on health-related quality of life in patients with heart failure with preserved ejection fraction and whether the clinical benefit observed with empagliflozin varies according to baseline health status.

methodsHealth-related quality of life was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline and 12, 32, and 52 weeks. Patients were divided by baseline KCCQ Clinical Summary Score (CSS) tertiles, and the effect of empagliflozin on outcomes was examined. The effect of empagliflozin on KCCQ-CSS, Total Symptom Score, and Overall Summary Score was evaluated. Responder analyses were performed to compare the odds of improvement and deterioration in KCCQ related to treatment with empagliflozin.

resultsThe effect of empagliflozin on reducing the risk of time to cardiovascular death or heart failure hospitalization was consistent across baseline KCCQ-CSS tertiles (hazard ratio, 0.83 [95% CI, 0.69-1.00], 0.70 [95% CI, 0.55-0.88], and 0.82 [95% CI, 0.62-1.08] for scores <62.5, 62.5-83.3, and ≥83.3, respectively;

conclusionsIn patients with heart failure with preserved ejection fraction, empagliflozin reduced the risk for major heart failure outcomes across the range of baseline KCCQ scores. Empagliflozin improved health-related quality of life, an effect that appeared early and was sustained for at least 1 year. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057951.

Indexed as

Health StatusQuality of LifeAgedAged, 80 and overBenzhydryl CompoundsFemaleGlucosidesHeart FailureHumansMaleMiddle AgedStroke VolumeVentricular Function, LeftBenzhydryl CompoundsempagliflozinGlucosidesempagliflozinhealth statusheart failure, diastolicquality of life

Identifiers

PMID34779658
PMCPMC8763045
OpenAlexW3213447899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.